Oncolytics Biotech (TSE:ONC) Stock Price Down 3.4% – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price dropped 3.4% on Wednesday . The stock traded as low as C$1.10 and last traded at C$1.13. Approximately 103,662 shares traded hands during mid-day trading, an increase of 2% from the average daily volume of 101,767 shares. The stock had previously closed at C$1.17.

Wall Street Analyst Weigh In

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The stock has a market cap of C$88.39 million, a price-to-earnings ratio of -3.03 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. The firm has a fifty day moving average of C$1.33 and a 200 day moving average of C$1.39.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.